ClinicalTrials.gg
CompletedNCT00284986Updated Oct 30, 2025

Safety and Efficacy of Prochymal for the Salvage of Treatment-Refractory Acute GVHD Participants

A Phase 2 interventional study of Prochymal in Graft Versus Host Disease, sponsored by Mesoblast, Inc.. Completed at 1 site in United States. Open to participants aged 6 Months to 70 Years. Per ClinicalTrials.gov, last updated 2025-10-30.

Sponsored by Mesoblast, Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Apr 2006, 20 years 6 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
11
Allocation
Not applicable
Ages
6 Months to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 454 studies in Graft vs Host Disease with a site in United States — 50 open to participants now, 71 under way, 2 of them phase 3. Graft vs Host Disease · United States.

Enrollment
284th of 389
11 · median 30
Started
2005
with 13 others
Phase 2
164 of 454
15 open now
Registered
107th of 454
by date

Among the 454 studies in Graft vs Host Disease with a site in United States, this one is the 284th largest by enrollment of the 389 interventional ones that give a count, is one of 14 that started in 2005, is one of 164 in phase 2, and was the 107th registered.

Graft vs Host Disease

804 studies on the registry are indexed under Graft vs Host Disease; 149 are open to participants now.

Browse Graft vs Host Disease studies →

Open to participants now

50 of the 454 studies in Graft vs Host Disease with a site in United States are open now. Recruiting first, the newest first:

45 more — sign in →

All 50 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 103 Graft vs Host Disease studies recruiting now, 51 (50%) set no upper age limit and 42 (41%) stop at 75 or younger; 42 take children under 18; 9 take healthy volunteers.

This study: 6 Months to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 454 studies in Graft vs Host Disease with a site in United States, or all of them as a file.
02

Study summary

This study is designed to evaluate the safety and efficacy of Prochymal® (Ex-vivo Cultured Adult Human Mesenchymal Stem Cells) in participants experiencing treatment-refractory acute GVHD, Grades III-IV, that is refractory to standard first-line therapies and at least one second-line therapy.

Read the detailed description

Allogeneic HSCT is used in the treatment of a variety of hematological, myeloproliferative and lymphoproliferative disorders, and malignancies involving solid tumors. Participants receiving HSCT can develop a life-threatening condition called GVHD. GVHD occurs when donor T cells from the donor bone marrow recognize host cells as "foreign" and initiate an inflammatory immunological response. The standard of care for treatment of acute GVHD consists of intravenous delivery of methylprednisolone starting on Day 1 and continuation of either cyclosporine or tacrolimus. This regimen of steroids and immunosuppressive drugs may relieve symptoms of GVHD, but some participants are refractory to current standard of care treatment. For treatment-refractory participants with grades III-IV GVHD mortality is approximately 80%. A therapy that could effectively suppress the immunological response from GVHD and help repair the damaged tissue could significantly decrease the mortality rate from this disease.

03

Conditions studied

  • Graft Versus Host Disease

Browse trials for

Keywords

  • GVHD
  • Graft vs Host Disease
  • Graft versus Host Disease
04

Who can participate

Ages eligible
6 Months to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must be 6 months to 70 years of age inclusive.
  • If female and of childbearing age, participants must be non-pregnant, not breast-feeding, and use adequate . Male participants must use adequate contraception.
  • Participants must have Grade III-IV acute that has failed to respond to standard first and at least one therapy. for confirmation of both skin and gastrointestinal GVHD is not mandatory, but is recommended when feasible. Enrollment should not be delayed awaiting biopsy results.
  • Participants must have minimal renal function as defined by: Calculated (CrCl) of > 30 milliliters/minute (mL/min) using the Cockcroft-Gault equation.
  • Participant must provide written and authorization for use and disclosure of protected health information (PHI).

Exclusion criteria

Exclusion Criteria:

  • Participant has uncontrolled alcohol or substance abuse within 6 months of treatment.
  • Participant has any underlying or current medical or psychiatric condition that, in the opinion of the Investigator, would interfere with the evaluation of the participant (e.g., uncontrolled infection, right heart failure, pulmonary hypertension, etc.).
  • Participant has a , unstable arrhythmia.
  • Participant has a known allergy to bovine or porcine products.
  • Participant is unwilling to sign consent form for the long-term follow-up study, protocol 271.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
11 participants (actual)

Study arms

  • Experimental
    PROCHYMAL™

    Drug: Prochymal

Interventions

  • Intravenous infusion of ex-vivo cultured adult human mesenchymal stem cells

06

What researchers measure

Primary outcomes

  1. Response by Day 28

    Responses included complete response (CR), partial response (PR), failure to respond. CR is defined as a complete resolution of graft-versus-host disease (GVHD). PR is defined as improvement in at least one organ by at least one full stage in the absence of progression in any other organ, or resolution of GVHD in at least one organ with a need for additional treatment because of abnormalities persisting in another organ. Failure to respond is defined as progression of GVHD.

    Time frame: Day 28

Secondary outcomes

  1. Improvement of GVHD by Day 28 in one or more organs involved with GVHD symptoms at day 1

    Time frame: Day 1

  2. Best stage of each involved organ by Day 28

    Time frame: Day 28

  3. Time to improvement or resolution of GVHD in one or more organs

    Time frame: Up to approximately 12 months

  4. Adverse events

    Time frame: Up to approximately 12 months

  5. Infusional toxicity

    Time frame: Up to approximately 12 months

  6. Overall relapse of underlying disease

    Time frame: Up to approximately 12 months

  7. Overall survival

    Time frame: Up to approximately 12 months

  8. Formation of ectopic tissue foci

    Time frame: Up to approximately 12 months

  9. Incidence of infection

    Time frame: Up to approximately 12 months

07

Study locations

1 site
  • Duke University
    Durham, North Carolina 27708, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2005 to primary completion in Apr 2006, 5 months.

Of 102 phase 2 interventional studies under Graft vs Host Disease, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 87. This study's 5 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 31, 2006
First posted
Feb 1, 2006
StartActual
Nov 18, 2005
Primary completionActual
Apr 25, 2006
CompletionActual
Feb 8, 2007
Last update
Oct 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00284986
Lead sponsor
Mesoblast, Inc.
Responsible party
Sponsor
First posted
Feb 1, 2006
Start date
Nov 18, 2005
Primary completion
Apr 25, 2006
Completion
Feb 8, 2007
Last update
Oct 30, 2025

Study contacts

Christopher James, PA
study director · Mesoblast, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Remestemcel-l

Start the discussion